Abstract
The current issue of Cancer includes a report on a concise, randomized controlled trial (RCT) with long‐term follow‐up that favors combined androgen blockade with bicalutamide versus lutenizing hormone‐releasing hormone monotherapy in Japanese men with locally advanced and metastatic prostate cancer. It has been 20 years since the first RCT on CAB was published, and the debate continues.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
